Compare NCMI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCMI | BCYC |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 360.7M |
| IPO Year | 2006 | 2019 |
| Metric | NCMI | BCYC |
|---|---|---|
| Price | $3.40 | $5.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $5.63 | ★ $13.90 |
| AVG Volume (30 Days) | 399.0K | ★ 574.3K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.55% | N/A |
| EPS Growth | ★ 52.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.20 | N/A |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.92 | $4.24 |
| 52 Week High | $6.18 | $9.55 |
| Indicator | NCMI | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 52.54 |
| Support Level | $3.17 | $5.03 |
| Resistance Level | $3.90 | $5.90 |
| Average True Range (ATR) | 0.14 | 0.25 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 85.71 | 90.50 |
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.